NRx Launches Preservative-Free Ketamine After FDA Approval
NRx Pharmaceuticals reported third quarter 2026 results on Tuesday, November 17, 2026. The Food and Drug Administration approved the company's preservative-free ketamine in October 2026, ahead of its November 10, 2026 goal date, and NRx began selling the drug the week of November 9 with a 17-person sales force. Third quarter net patient service revenue was $1.2 million, and the net loss narrowed to $2.2 million, or $0.05 a share.
Edited and fact-checked by Stephen Sprague
NRx crossed the line from development company to seller in one quarter. Its first approved drug is a hospital staple, ketamine, and its pitch is packaging: a plastic vial that costs about $0.75 to fill against about $3.25 for glass.
A sales representative walked into a hospital purchasing office the week of November 9 carrying NRx's first approved drug. The company reported the launch on Tuesday, November 17, 2026, in its third quarter update, and it has received its first order. Shipments are scheduled to begin no later than January 2027.
The Food and Drug Administration approved NRx's abbreviated application for preservative-free ketamine in October 2026, ahead of the November 10, 2026 goal date in the approval process. It is the company's first drug approval. The product is a sterile injectable form of ketamine, a hospital anesthetic that has been in clinical use for decades, so the approval rests on the company's formulation and packaging rather than on a new molecule.
The packaging is the commercial argument. The drug ships in a blow-fill-seal vial with a luer-lock connection, developed with Nephron Pharmaceuticals, which lets a clinician draw the medication into a syringe without a needle and removes needle related sharps waste. NRx estimates its cost of goods at about $0.75 a unit in this packaging against about $3.25 a unit in glass, based on its prior experience with glass vials. Those cost figures are the company's own estimates, not audited results.
NRx estimates the current U.S. market for sterile injectable ketamine at about $400 million, growing at more than 15 percent a year. The company says it intends to add other already approved sterile products in 2027, which it believes could double that market opportunity. A 17-person sales force is calling on hospitals and group purchasing organizations, the buyers who decide which supplier's version of a standard drug a hospital stocks.
The quarter's financial results describe a company still funded by investors rather than by sales. Net patient service revenue, from the company's HOPE Therapeutics clinics in Florida, was $1.2 million against $0.2 million a year earlier. The net loss narrowed to $2.2 million, or $0.05 a share, from $5.9 million and $0.27 a share, while the loss from operations widened to $8.1 million from $4.0 million as selling and administrative costs rose to $6.6 million ahead of the launch. Cash was $19.8 million at September 30, 2026, with no convertible debt.
Two pipeline items carry the company's next claims, and both are plans rather than results. NRx signed a collaboration with Yale University, with the written approval of the Patient-Centered Outcomes Research Institute, to join a five-year study comparing intravenous ketamine with intranasal S-ketamine, and it aims to submit a rolling application for its NRX-100 presentation by the end of 2026. A new product, NRX-200, is a subcutaneous ketamine formulation with pharmacokinetic testing expected in early 2027 and a first human trial targeted for September 2027. None of those dates is an approval, and the update does not present patient outcome data for either product.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.